Haemophilic factors produced by transgenic livestock: Abundance that can enable alternative therapies worldwide

Haemophilia, Supplement

Volumn 10, Issue 4, 2004, Pages 70-76

  Van Cott, K E ^b   Monahan, P E ^a   Nichols, T C ^a   Velander, William H ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c NONE   (United States)

Author keywords

Factor IX; Haemophilia; Transgenic animal

Indexed keywords

BLOOD CLOTTING FACTOR 9; LIPOSOME; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG COST; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG PURIFICATION; FOOD DRUG INTERACTION; GENETIC ENGINEERING; HEALTH ECONOMICS; HEMOPHILIA; HUMAN; LIVESTOCK; MAMMARY GLAND; MILK; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SWINE; TRANSGENIC ANIMAL;

EID: 11044224174     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00983.x     Document Type: Article

References (36)

1. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10 (Suppl. 1): 63-70.
2. Fischer K, Van Der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8 745-52.
3. Mannucci PM. Hemophilia: treatment options in the twenty first century. J Thromb Haemost 2003; 1: 1349-55.
4. Linden JV, Kolakoski MH, Du Lima JEP, Lipton RA. Factor concentrate usage in persons with hemophilia in New York State. Transfusion 2003; 43: 470-5.
5. Drug Topics Red Book. Montvale, NJ: Medical Economics, 2003.
6. Frantz S. Why are clinical costs so high? Nat Rev Drug Discov 2003; 2: 851-2.
7. Miners AH, Sabin CA, Tolley KH, Lee CA. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med 2000; 247: 493-9.
8. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
9. Suttie JW. Synthesis of vitamin K-dependent proteins. FASEB J 1993; 7: 445-52.
10. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-8.
11. Harrison S, Adamson S, Bonam D et al. The manufacturing process for recombinant factor IX. Semin Hematol 1998; 35 (Suppl. 2): 4-10.
12. Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35 (Suppl. 2): 11-7.
13. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
14. Varki A, Cummings R, Esko Jeffrey; Freeze H, Hart G, Marth J. Essentials of Glycobiology. Plainview (NY): Cold Spring Harbor Laboratory Press, 1999.
15. Makino Y, Omichi K, Kuraya N et al. Structural analysis of N-linked sugar chains of human blood clotting factor IX. J Biochem (Tokyo) 2000; 128: 175-80.
16. Miao HZ, Sirachainan N, Palmer L et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412-9.
17. Tendulkar R, Pipe SW, Miao H, Kaufman RJ. Asparagine-linked glycosylation sites within the B domain of coagulation Factor VIII improve secretion efficiency. Blood 2001; 98: 705.
18. Garber K. rFactor VIII deficit questioned. Nat Biotechnol 2000; 18: 1133.
19. Garber K. Biotech industry faces new bottleneck. Nat Biotechnol 2001; 19: 184-5.
20. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26.
21. Lubon H, Paleyanda RK, Velander WH, Drohan WN. Blood proteins from transgenic animal bioreactors. Transfus Med Rev 1996; 10 131-43.
22. Lindsay M, Gil G, Zhang C, Cadiz A, Velander WH, Van Cott KE. Purification of recombinant DNA-derived Factor IX and fractionation of active and inactive subpopulations. J Chromatogr 2004; 1026: 149-57.
23. Paleyanda RK, Velander WH, Lee TK et al. Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol 1997; 15: 971-5.
24. Clark AJ, Bessos H, Bishop JO et al. Expression of human anti-hemophilic factor IX in the milk of transgenic sheep. Biotechnology 1989; 7: 487-92.
25. Spik G, Coddeville B, Mazurier J, Bourne Y, Cambillaut C, Montreuil J. Primary and three-dimensional structure of lactotransferrin (lactoferrin) glycans. Adv Exp Med Biol 1994; 357: 21-32.
26. Edmunds T, Van Patten SM, Pollock J et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91 4561-71.
27. Levy JH, Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 2001; 27: 405-16.
28. Ziomek CA. Minimization of viral contamination in human pharmaceuticals produced in the milk of transgenic goats. Dev Biol Stand 1996; 88: 265-8.
29. Giangrande PL, Kessler CM, Jenkins CE, Weatherill PJ, Webb PD. Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia 2002; 8: 798-801.
30. Wells GA, Hawkins SA, Austin AR et al. Studies of the transmissibility of the agent of bovine spongiform encephalopathy to pigs. J General Virol 2003; 84: 1021-31.
31. Russell KE, Read MS, Bellinger DA et al. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thromb Haemost 2001; 85 445-9.
32. Liles D, Landen CN, Monroe DM et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost 1997; 77: 944-8.
33. McCarthy K, Stewart P, Sigman J et al. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 2002; 87: 824-30.
34. Hemker HC, Hermens WT, Muller AD, Zwaal RF. Oral treatment of haemophilia A by gastrointestinal absorption of factor VIII entrapped in liposomes. Lancet 1980; 1: 70-1.
35. Horikoshi I, Sakuragawa N, Ueno M, Takahashi K. Pharmaceutical Composition for Oral Administration Containing Coagulation Factor VIII or IX. US Patent 4183960, 1982.
36. National Hemophilia Foundation. Research and development of improved coagulation products that would expedite the transition to total prophylaxis for all persons with coagulation disorders are strongly encouraged. Available at: http://www.hemophilia.org/research/masac/masac151.htm